MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 25812-30-0
MCE 国际站:Gemfibrozil
产品活性:Gemfibrozil 是一种 PPAR-α 激活剂,为一种降脂剂;Gemfibrozil 同时是 P450 的非选择性抑制剂,对 CYP2C9,2C19,2C8 和 1A2 的 Ki 值分别为 5.8,24,69 和 82 μM。
研究领域:Cell Cycle/DNA Damage | Vitamin D Related/Nuclear Receptor | Metabolic Enzyme/Protease
作用靶点:PPAR | Cytochrome P450
In Vitro: Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering drug; also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively. Gemfibrozil (100, 150, 200 μM) inhibits the cytokine-induced NO production in a concentration dependent manner in human U373MG astroglial cells, and such effects are not due to any change of the stability of iNOS mRNA. Gemfibrozil (50, 100, 200 μM) inhibits human iNOS promoter-derived luciferase activity in cytokine-stimulated human U373MG astroglial cells. Furthermore, Gemfibrozil (50, 100, 150, and 200 μM) shows no effects on the viability of the cells. Gemfibrozil considerably inhibits both M-23 and M-1 formation (catalyzed by CYP2C8 and CYP3A4), with Ki (IC50) values of 69 μM (95 μM) and 273 μM (>250 μM), respectively, in human liver microsomes. Gemfibrozil (0-250 μM) dose dependently inhibits the formation of M-23 (IC50, 68 μM) and M-1 (IC50, 78 μM) in recombinant CYP2C8, but shows no appreciable effect on the formation of these metabolites in recombinant CYP3A4.
In Vivo: Gemfibrozil (62 mg/kg/day, p.o.) treatment initiated 3 days before spinal cord injury (SCI) causes decreased locomotor function, and induces a trend for decreased white matter sparing after injury in mice. Gemfibrozil (62 mg/kg/day, p.o.) decreases macrophage immunoreactivity but increases T cell infiltration into spared tissue.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Metabolism/Protease Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Antioxidant Compound Library | Anti-diabetic Compound Library | Oxygen Sensing Compound Library | Anti-Cardiovascular Disease Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Transcription Factor-Targeted Library | Lipid Metabolism Compound Library | Tumorigenesis-Related Compound Library | Rare Diseases Drug Library | Antidepressant Compound Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Nuclear Receptor Compound Library | Off-patent Drug Library | Mitochondrial Protection Compound Library | Mitochondrial Toxicity Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | PC945 | Mephenytoin-d5 | AMG-208 | Doxepin-d3 hydrochloride | LY518674 | Hypericin | Bocidelpar | EMT inhibitor-2 | Retinoic acid | 5-Aminosalicylic Acid-d3 hydrochloride | Atazanavir | Naveglitazar | Galeterone | Ertiprotafib | CYP1B1-IN-2 | ATRA-biotin | Bergapten | Fadrozole hydrochloride | Ginsenoside Rd | Convallatoxin | MHY908 | ML252 | Ezutromid | Seviteronel | 4-(Trifluoromethyl)umbelliferone | Ciprofibrate | Chlorpromazine hydrochloride | BVT948 | MK-886
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
货号: HY-B0258
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。